Seeking Alpha

D. Mero

View as an RSS Feed
View D. Mero's Comments BY TICKER:
Latest comments  |  Highest rated
  • Checking In On The Mispriced Inovio [View article]
    The milestone payments come with a lot of uncertainty, especially the ones further out. So obviously there is a possibility that Inovio does not receive another dime from Roche in case of termination.

    With that being said, Inovio has proven time and time again its more than "petri dish and some mice studies". In its extended existence, the company has managed to sign deals with some big names (Roche, J&J, US military, UPenn, Gates Foundation... list goes on). Heck, in the last 5 years external funding has brought in almost $60 million. Either these institutions are blindly throwing money at Inovio or they see something that you are missing.
    Oct 21 10:41 PM | 10 Likes Like |Link to Comment
  • The Real Reason Apple Is Acquiring Beats For $3.2B - Part 2 [View article]
    Great analysis. At a first glance, Apple's acquisition doesn't make complete sense. However, once you dig in a little deeper, it's a great move. Your projected numbers show that.

    The hardware business has a renouned brand, is growing, high margined and profitable. If that alone wasn't enough, Apple is also getting two of the most powerful icons in music on board and has Beats Music as a potentially lucrative call option if it pans out.
    May 20 12:51 PM | 7 Likes Like |Link to Comment
  • Organovo's Opportunities Validate Rising Valuation [View article]
    Maybe you missed it, but I've argued that revenues at this stage are not as significant as the collaborations they bag. The company has entered into several in the last couple months. Priority for Organovo is to continue developing their bioprinter, which they are doing through every collaboration they enter. In time, if the bioprinter proves to provide superior tissue, revenues will come with the continued collaborations. If you're looking for an investment with steady revenue streams, I suggest you look away from developing tech/biotech companies.

    To understand Organovo's CRO approach, listen to the latest presentation. They specifically mention expansion into this research area. The company has $50+M in cash. I'm sure they won't have too hard of a time growing that 31-employee number.
    Jan 21 10:24 AM | 6 Likes Like |Link to Comment
  • Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014 [View article]
    Inovio has an agreement with OncoSec for the intellectual property relating to electroporation technology. In return, OncoSec will pay Inovio cash fees and a royalty on commercial product sales.

    ONCS success could prove to be a validation of the electroporation technology. So, it could be possible that success of ONCS will have an effect on Inovio price. However, Inovio's success should not have any bearing on OncoSec price. Remember that ONCS licenses the old electroporation device.
    Dec 21 10:57 AM | 5 Likes Like |Link to Comment
  • Why I Bought Ebix Ahead Of Earnings [View article]
    "Many of you have asked the company for an update on the SEC and DOJ front. The company can report that it had not been asked for any additional information from either the SEC or the U.S. Attorney's Office since 2013. Also, the company is not aware of any further investigative steps by the SEC or by the U.S. Attorney's Office since 2013."

    Smoke is slowly fading thereby showing that there is little risk with EBIX regarding regulatory bodies. In a market such as today's, where many stocks are overvalued based on metrics, EBIX offers investors a great opportunity. Potential upside here is much greater than downside.
    Aug 8 02:47 PM | 4 Likes Like |Link to Comment
  • Uplisting To Expand Organovo's Valuation [View article]
    I appreciate the comment and am quite aware of NVIV . They do share similar features to ONVO in a sense that they operate in unique sectors where they are the only viable options for investors. Additionally, they have taken steps (such as clearing their B/S with the exercised warrants) that point to an uplisting- similar to what ONVO did at the start of 2013.

    With that being said though, the company is up almost 200% YTD. I would hesitate to initiating any sort of position (long/short) due to that momentum run.

    I encourage you to continue your research on the company and share your findings through SeekingAlpha contributions rather than comments on another company's article. Not only would you be exposed to a greater viewing, but also eliminate the perception of "pumping" the stock. Best of luck
    Jul 16 09:56 AM | 4 Likes Like |Link to Comment
  • Could Upcoming Catalysts Carry On The Epic Year For Inovio? [View article]
    No exact date has been given Amar, but I will be keeping an eye on any reports that come out of the OneMedForum conference this week to see if Inovio is providing any further guidance.
    Jun 26 10:26 AM | 4 Likes Like |Link to Comment
  • Nuance A Misunderstood Name That Could Double In 2014 [View article]
    Good point in regards to Nuance's high debt level. Though I think debt is a concern for the company, it is lower on the "priority list". In my opinion, the market's caution on Nuance is due to their declining financial results (mainly caused by transition to subscription revenue) and lack of trust in management.

    Investors are hopeful that presence of an activist investor like Icahn can pressure management to cut costs and run leaner operations. This will in turn make the transition smoother and therefore provide better financial results. Replacing the CEO is another prayer investors are hoping gets answered in 2014. If these two factors can be improved, I believe debt will be a manageable figure that will decline with time.
    Dec 17 06:37 PM | 3 Likes Like |Link to Comment
  • Are You Buying The 3D Printing Hype? [View article]
    I appreciate your comment and agree with you that 3D printing is still a relatively unknown technology amongst the general public.

    However, the current price of DDD, as shown by the P/E and PEG, indicate that it may be too high for the current earnings the company has reported to date. The growth of the stock price has outpaced earnings growth. This could be due to the "hype". If so, the price you would be paying includes this premium.

    I am a firm believer in the company and the 3D printing technology. I think both have a very bright future with limitless potential. That being said, I think there will be a better time for longs to enter when the stock isn't as hot as it is now so they can maximize profits. This is only my opinion.

    Speaking of 3D food, here is an interesting article.
    Sep 7 07:18 PM | 3 Likes Like |Link to Comment
  • Nuance A Misunderstood Name That Could Double In 2014 [View article]
    Ricci is both the CEO and Chairman of the board. Like you said, the board is on Ricci's side as they've let the shareholders get stepped on. Appointing two independent members from Icahn's team was a step in the right direction. I'm interested to see if anything of substance will come out of the 2014 Shareholders meeting
    Dec 18 09:22 AM | 2 Likes Like |Link to Comment
  • Tech And Healthcare: Eye Catching Themes Of Early April [View article]
    Keep in mind this is being written 7months after I wrote this article. During that time, ONVO has has uplisted and continued building value.

    The lack of news from Pfizer has been surprising. No further details have been given so its possible that no further collaboration is in future. Last I heard at the RetailInvestor Conference chat, Murphy said the results are being reviewed. Does the silence mean Pfizer wasn’t pleased? Maybe. Should be interesting to see what CEO Murphy has to say regarding this at the upcoming Dec 5 presentation.

    Safely assuming no more grants due to one quarter is quite short sighted even for the most bearish investor. One deal could get this number back up to the hundred thousand mark. In either case, its not the decisive figure in making investment decisions on ONVO.

    The company has collaborated with several large names recently. Although no revenue has been recorded, this is a R&D company after all. These collaborations prove to be a cheap way of advancing the technology. Investors of ONVO are not buying because of its fundementals but rather the potential of technology.

    The run up to $1B valuation was irrational. Most will agree with you there. The technology, if it proves to be the real deal, will reach potential in distant future. The CEO himself has said that this will take time, even citing a possible 10 years. ONVO has been a volatile company so its up to investors to decide whether to risk trading the swings or invest long term. In the long term, I believe the uptrend will continue.

    Organovo plans to launch an initial 3D liver tissue assay product in 2014, followed by a series of additional tissue assay products. This will provide the company with a potential $500 million market opportunity by 2018. That does not mean they will hit sales of $500 million by 2018. Organovo believes this will bring annual revenue into the “tens of millions”. I believe the market will be higher than the “at best 2-4M a year range” you claim. IMO, these figures may be accurate when the assay first comes out in 2014/2015, but will reach sales closer to the company’s projection into tens of millions afterwards. Obviously, all these projected figures are subject to change as we are looking years into the future.

    The excitement around ONVO is warranted. It is the only public company involved in the hot industries of 3D printing and biotech. Being the the only company that investors like you and I can get in on the 3D printing/biotech action results in a valuation premium. This premium, at times, gets out of hand which is when investors need to be cautious
    Nov 20 11:10 AM | 2 Likes Like |Link to Comment
  • One's Trash Is Another's Treasure [View article]
    Consumer electronics, like the smartphone, have become widely adopted. The demand for these products has shifted to the emerging markets, where the majority of growth is driven by lower priced phones. With its current pricing strategy, Apple is pricing itself out of the segment that is experiencing the most growth.

    Yes, Apple will continue to attract the rich to buy its phones, but so will its competitors who are also offering high end phones with similar features. Apple is facing increased competition for the high end market. The same cannot be said with Apple in the low end market however, since they are not at all involved.

    Using your car analogy, Honda, Toyota and Nissan have luxury vehicles Acura, Lexus and Infiniti. With their diverse range of products, these companies can target all demographics. Similarly, ZTE and other "low end manufacturers" offer high end lines like the Grand S to tailor the privileged.

    These are two different approaches to tap into the emerging markets. Time will tell which will work, or work more effectively. The point I am making is that the strategy to target all consumers, including the ones contributing the greatest growth, may end up being a lost opportunity for Apple yet rewarding for rivals.
    Sep 27 03:48 PM | 2 Likes Like |Link to Comment
  • Organovo's Focus On Long-Term Value Creation Going Unnoticed [View article]
    Good point Mickle. I'm paraphrasing but Keith Murphy, during the webcast, said something along the lines of investors should not fear dilution if it's money being well spent. Thus far, Organovo has returned a good value multiple on the money they have raised. This should continue.
    Sep 12 04:54 PM | 2 Likes Like |Link to Comment
  • Inovio's Hepatitis C Data: What Does It Really Mean? [View article]
    It is clear, as many other comments above have proved, that this author is making an effort to sabotage by posting misleading information. For someone this "credible", how can they claim the hepatitis C study vaccine is Inovio's. Even the press release states clearly,

    "The vaccine was developed by ChronTech AB of Sweden, and the companies are using a device made by Inovio to help get the vaccine into cells at a greater rate"

    Also, if the author may be as kind as to clarify this:

    "Inovio Pharmaceuticals, however, caught my eye a while back when it started making overly positive statements about a platform (DNA vaccines) that has failed repeatedly in Phase II human trials. "

    Is this stating INO has repeatedly failed in Phase II human trials? Or other DNA vaccines have?
    Apr 5 06:10 PM | 2 Likes Like |Link to Comment
  • 3D Systems Scrutiny Highlights Promise For 3D Bioprinting [View article]
    I plan on adding to my position at levels in the low 3 range. I have frequently traded the stock so there is no single purchase price. However, my latest purchase price was at $4.40 before this recent fall.

    My opinion is as credible as the next investor's though, so it should be taken with a grain of salt.
    Mar 14 07:52 PM | 2 Likes Like |Link to Comment